All In Biotech

Drug Trial Radar · NCT06223841

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

A Clinical Trial of Phase Ib/II to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Mar 1, 2026

Study completion Mar 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • IAP0971Drug

    IAP0971 should be subcutaneous injected,q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events (AEs) and SAEs (Phase Ib)Time frame: 3 months after end event visit
  2. Dose limiting toxicities (DLTs) (Phase Ib)Time frame: 21 days after first dose
  3. PFS in dose expansion (Phase II)Time frame: Baseline through up to 2 years or until disease progression

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.